Overview
On 26 February 2019, orphan designation (EU/3/19/2134) was granted by the European Commission to FGK Representative Service GmbH, Germany for 9-cis, 12-cis-11,11-D2-linoleic acid ethyl ester (also known as RT001) for the treatment of infantile neuroaxonal dystrophy.
Key facts
Active substance |
9-cis, 12-cis-11,11-D2-linoleic acid ethyl ester
|
Intended use |
Treatment of infantile neuroaxonal dystrophy
|
Orphan designation status |
Positive
|
EU designation number |
EU/3/19/2134
|
Date of designation |
26/02/2019
|
Sponsor |
FGK Representative Service GmbH |
Patients' organisations
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
EU register of orphan medicines
The list of medicines that have received an orphan designation in the EU is available on the European Commission's website: